Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin

Abstract

Objective: To compare extra glycaemic effects of dapagliflozin and empagliflozin in Type 2 Diabetes mellitus.

Study Design: Quasi-experimental study.

Place and Duration of Study: Pharmacology Department, Army Medical College, in collaboration with Endocrine Department, Pak Emirate Military Hospital, Rawalpindi Pakistan, from Sep 2021 to Jan 2022.

Methodology: One hundred and twenty diabetic patients were recruited strictly according to inclusion and exclusion criteria. They were randomly alienated into two groups (A & B) by lottery method and were prescribed oral dapagliflozin and empagliflozin 10 mg/day each for four weeks, respectively. Serum uric acid, erythropoietin levels, and weight were recorded on day 0 and after four weeks of treatment.

Results: There were statistically significant differences in weight (p-value=0.004) and erythropoietin levels (p-value=0.027). However, an inconsequential variance was observed in serum uric acid levels Uric Acid (p-value=0.365) between the two groups after four weeks of treatment with dapagliflozin and empagliflozin.

Conclusions: Dapagliflozin and empagliflozin have significantly improved weight, erythropoietin and serum uric acid levels. Moreover, Dapagliflozin is superior to Empagliflozin in improving weight and erythropoietin levels and has almost equivalent efficacy in improving uric acid levels in T2DM patients.
Keywords: Dapagliflozin; Empagliflozin; SGLT2 inhibitors; Type 2 diabetes mellitus.